A recent study by Mejri N et al. highlights critical lung cancer sex disparities across the entire clinical care continuum. Although lung cancer traditionally affects more men, women represent a growing portion of cases globally. Specifically, in low- and middle-income countries, these disparities remain complex. Understanding these gaps is essential for optimizing oncological outcomes in diverse patient populations.

Diagnostic Challenges and Patient Intervals

Research indicates that women often face significant diagnostic delays despite presenting at a younger age. Notably, the Tunisian cohort study showed that women experienced longer patient intervals and diagnostic intervals compared to men. However, once women entered the healthcare system for treatment, the intervals became comparable. These findings suggest that lung cancer sex disparities in the early care pathway may stem from lower clinical suspicion in female non-smokers.

Molecular Testing and Targeted Therapy

In contrast to the diagnostic delays, women often benefit from more comprehensive molecular profiling. Clinicians more frequently order biomarker testing for female patients. Consequently, women are more likely to receive targeted therapies. Similarly, Indian studies by Ghosh et al. confirm that females exhibit a higher prevalence of adenocarcinoma and EGFR mutations. Therefore, the integration of molecular diagnostics is vital for addressing biological differences between sexes.

Survival Outcomes and Biological Factors

Despite facing longer diagnostic gaps, women consistently demonstrate superior overall survival. The median survival in the Tunisian study reached 20 months for women compared to 14 months for men. This survival advantage persists even after adjusting for age and smoking intensity. Researchers suggest that biological susceptibility and differential responses to therapy play a role. Moreover, the increased access to targeted treatments significantly enhances female survival rates in non-small cell lung cancer (NSCLC).

Addressing Lung Cancer Sex Disparities in Practice

Healthcare providers must recognize that lung cancer symptoms in women may be dismissed or attributed to other conditions. Increasing awareness among general practitioners is a critical step. Furthermore, clinicians should maintain a high index of suspicion for NSCLC in young, non-smoking females. Implementing standardized diagnostic protocols can help reduce the current inequities in the care pathway.

Frequently Asked Questions

Why do women experience longer diagnostic delays in lung cancer?

Women often face delays because they are more likely to be non-smokers and younger at presentation. Consequently, clinicians may have a lower initial suspicion of malignancy compared to their approach with older male smokers.

Do women have better survival rates in NSCLC?

Yes, multiple studies indicate that women generally have longer median overall survival than men. This is often attributed to a higher frequency of targetable mutations and different biological responses to treatment.

Is molecular testing more common in female lung cancer patients?

Yes, data shows women more frequently undergo biomarker testing. This trend occurs because certain driver mutations, such as EGFR, are significantly more prevalent in the female population.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Mejri N et al. Sex-based inequities in non-small cell lung cancer: gaps and opportunities across the care pathway. Clin Transl Oncol. 2026 Jun 07. doi: 10.1007/s12094-026-04449-8. PMID: 42251629.

Ghosh T et al. Lung cancer in Asian Indian females: Identification of disease-specific characteristics and outcome measures over a 12-year period. JCO Glob Oncol. 2022 Dec;8:e2200231.

Jain A et al. Epidemiology of EGFR Mutation in Adenocarcinoma NSCLC Patients in India: A Systematic Review and Meta-Analysis. Adv Lung Cancer. 2024;13(1):1-21.